PepKon Showcases Its Cutting-Edge Peptide Therapeutics at NETVA 2024 in Boston

PepKon is thrilled to have participated in the NETVA 2024 Immersion Week in Boston, organized by the Consulate General of France in Boston and Business France Healthcare - North America. This event provided a unique opportunity to explore Boston’s biotech ecosystem and highlight PepKon’s pioneering work in peptide-based oncology treatments.

The week featured an exciting pitching session, where PepKon’s CEO, Jonathan Levy, shared insights into our next-generation peptide therapeutics, alongside other innovative startups. Discussions focused on AI-powered peptide drug discovery, computational peptide modeling, and targeted peptide cancer treatments.

We also engaged with InnoVenture Labs and visited Ginkgo Bioworks, gaining valuable insights into AI-driven peptide platforms and oncological peptide drug development.

As a biotech company specializing in peptide therapeutics development, PepKon remains committed to advancing AI-assisted peptide discovery and oncology-focused peptide engineering. The connections forged at NETVA 2024 pave the way for exciting collaborations, driving our mission to develop groundbreaking peptide-based cancer therapies.

Stay tuned for more updates as we push the boundaries of peptide pharmaceuticals!

‍